COCPs for PMOS

Combined oral contraceptives serve as first-line pharmacotherapy for non-fertility management. They suppress pituitary luteinizing hormone secretion to arrest ovarian theca-cell androgen synthesis while stimulating hepatic sex hormone-binding globulin production, drastically reducing bioactive free testosterone. This concurrent action mitigates hirsutism, restores cyclic withdrawal bleeding, and provides essential endometrial protection against unopposed estrogen-driven hyperplasia.